The FDA has approved the first generic versions of Fosamax (alendronate sodium tablets), used to treat osteoporosis. Osteoporos is a condition that causes thinning and weakening of bones and is often one of the many significant side effects from Hormone Therapy.
Teva Pharmaceuticals USA has received approval to manufacture alendronate sodium tablets in three once-daily dosing strengths (5 milligrams, 10 milligrams, and 40 milligrams) and two once-weekly strengths (35 milligrams and 70 milligrams). Barr Laboratories, Inc., was approved to manufacture a 70-milligram, once-weekly, dose of the drug.
The FDA’s complete newsrelaease can be seen at: FDA approves generic Fosamax
The next time you have your prescription renewed ask your physician if if it can be written generically – Save some money.
Joel T Nowak MA, MSW